• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>IEEE International Conference on Control Automation >Clinical study on saccharomyces boulardii in the treatment of patients with mild to moderate ulcerative colitis
【24h】

Clinical study on saccharomyces boulardii in the treatment of patients with mild to moderate ulcerative colitis

机译：布拉氏酵母菌治疗轻度至中度溃疡性结肠炎的临床研究

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim: To investigate the clinical therapeutic efficacy of saccharomyces boulardii(Sb) in combination with mesalazine in patients with mild to moderate ulcerative colitis (UC). Methods: Sixty patients aged 18 to 75 years with mild to moderate UC were divided into two groups, the combination group and the mesalazine group. Clinical remission rate (CRR) was calculated with the formula: CRR= number of complete remission cases + number of effective cases)/all cases. The clinical symptom score (CSS), endoscopic score (ES) and histopathological score (HS) were recorded before and after treatment. Result: After two week's treatment, the CSS in the combination group was significantly decreased (P<0.05), but in the mesalazine group it showed no significant changes (P>0.05). After four week's treatment, the CSS in both combination group and mesalazine group was significantly decreased(P<0.05). After 8 week's treatment, the CSS, ES and HS in the combination group were significantly lower than those in the mesalazine group(P<0.05). CRR in the combination group (46.7%) was significantly higher than that in the mesalazine group (20.0%) after 8 weeks' treatment (P<0.05). Conclusion: Saccharomyces boulardii in combination with mesalazine is faster and more effective in improving clinical symptoms, endoscopic and histopathological changes in patients with mild to moderate UC than using mesalazine alone.
机译：目的：探讨博拉德酵母（Sb）与美沙拉嗪联合治疗轻度至中度溃疡性结肠炎（UC）的临床疗效。方法：将60例18至75岁的轻度至中度UC患者分为两组，即联合治疗组和美沙拉嗪治疗组。临床缓解率（CRR）的计算公式为：CRR =完全缓解病例数+有效病例数/所有病例。记录治疗前后的临床症状评分（CSS），内镜评分（ES）和组织病理学评分（HS）。结果：治疗2周后，联合组的CSS明显降低（P <0.05），但美沙拉嗪组无明显变化（P> 0.05）。治疗4周后，联合用药组和美沙拉嗪组的CSS均明显降低（P <0.05）。治疗8周后，联合组的CSS，ES和HS明显低于美沙拉嗪组（P <0.05）。治疗8周后，联合组的CRR（46.7％）显着高于美沙拉嗪组（20.0％）（P <0.05）。结论：与单独使用美沙拉嗪相比，布拉氏酵母与美沙拉嗪联合使用可更快，更有效地改善轻度至中度UC患者的临床症状，内镜和组织病理学变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号